The Australian medical sector is abuzz with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor showing impressive results in clinical trials for managing obesity. This therapy suggests a https://webnowmedia.com/story7251529/the-new-retatrutide-australia-a-potential-hope-for-obesity-treatment